TrialInternational journal of molecular sciences2019

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.

Koutaro Yokote et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.